This can be huge and cause many to switch treatments. Chronic kidney failure is a major problem, leading to both suffering and high costs.”
Johan Jendle, Professor, Örebro University
A glucose-lowering drug commonly used in patients with type 2 diabetes, can protect the kidneys in patients with type 1 diabetes. According to results shown in a new study published in the Lancet.
“This can be huge and cause many to switch treatments. Kidney failure is a major problem, causes both suffering and high costs. But further studies are needed to confirm these findings,” says Johan Jendle, professor at örebro University.
Dapagliflozin has shown to protect the kidneys in patients with type 2 diabetes and researchers want to find out if it has the same effect in subjects with type 1 diabetes. The new study included two hundred fifty-one patients with type 1 diabetes and with increased levels of protein in the urine. The participating patients were divided into three groups: one group received a placebo, another received a low dose of dapagliflozin, 5 mg, and the third received a slightly higher dose, 10 mg. Researchers then compared the protein levels in the urine of the participants.
Continue –> here